About 11 results found for searched term "PARP" (0.088 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M13712 | PARP1-IN-5 dihydrochloride | PARP |
| PARP1-IN-5 dihydrochloride is a low toxicity, orally active, potent and selective PARP-1 inhibitor (IC50 =14.7 nM). PARP1-IN-5 dihydrochloride can be used for the research of cancer. | ||
| M29181 | PARP14 inhibitor H10 | PARP |
| PARP14 inhibitor H10, compound H 10, is a selective inhibitor against PARP14 (IC50=490 nM), over other PARPs (≈24 fold over PARP1). PARP14 inhibitor H10 induces caspase-3/7-mediated cell apoptosis. | ||
| M29548 | PROTAC PARP1 degrader | PROTAC |
| PROTAC PARP1 degrader is a PARP1 degrader based on MDM2 E3 ligand. It induces significant PARP1 cleavage and programmed cell death. PROTAC PARP1 degrader at 10 μM at 24 h inhibits MDA-MB-231 cell line with an IC50 of 6.12 μM. | ||
| M41360 | PARP-1/2-IN-2 | PARP |
| PARP-1/2-IN-2-IN-1 is a PARP1/2/CDK12 inhibitor (IC50: 34, 30 and 285 nM respectively). | ||
| M41572 | PARP-1-IN-3 | PARP |
| PARP-1-IN-3, a benzamide derivative, is a potent PARP-1 inhibitor with IC50 values of 0.25 nM and 2.34 nM for PARP-1 and PARP-2, respectively. | ||
| M41575 | PARP1-IN-14 | PARP |
| PARP1-IN-14 is a potent PARP1 inhibitor, with an IC50 of 0.6 ± 0.1 nM. | ||
| M41577 | PARP-1-IN-13 | PARP |
| PARP-1-IN-13 is a PARP-1 inhibitor (IC50: 26 nM). | ||
| M41578 | PARP-1-IN-4 | PARP |
| PARP-1-IN-4 is a PARP-1 inhibitor. | ||
| M42940 | ARTD3/PARP3-IN-1 | Others |
| ARTD3/PARP3-IN-1 is an unselective inhibitor of diphtheria toxin-like ADP-ribosyltransferase 3 (ARTD3)/PARP3. | ||
| M43519 | VEGFR/PARP-IN-1 | PARP |
| VEGFR/PARP-IN-1 is a VEGFR/PARP dual inhibitor (IC50s: 191 nM and 60.9 nM respectively). | ||
| M45107 | PARP/EZH2-IN-1 | PARP |
| PARP/EZH2-IN-1 is a first-in-class dual PARP (IC50 6.87 nM) and EZH2 (IC50 36.51 nM) inhibitor for triple-negative breast cancer with wild-type BRCA. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
